Market Cap 155.71M
Revenue (ttm) 11.16M
Net Income (ttm) -148.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,327.33%
Debt to Equity Ratio 0.00
Volume 557,100
Avg Vol 1,867,864
Day's Range N/A - N/A
Shares Out 99.18M
Stochastic %K 20%
Beta 2.38
Analysts Strong Sell
Price Target $11.86

Company Profile

Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Ho...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 982 6030
Address:
2929 7th Street, Suite 105, Berkeley, United States
HughGeez
HughGeez Aug. 18 at 11:34 AM
$CRBU I am no expert on Altimmune but didn't Altimmune drop because of mixed phase 2 results? We don't have that with CRBU. Also even though they had mixed phase 2 results the stock price is $3 with much higher market cap.
0 · Reply
cta7978
cta7978 Aug. 18 at 8:13 AM
$CRBU 3 quarters "exploring financing options", then last quarter dilluting nearly 10% at low stock price (~$2.03).. I fear they are going to have to go it alone.. Don't really understand why? I held Altimmune a few years ago, everyone was hoping for a partnership or a big pharma deal after phase 2, then everything just died and they did massive dilution and screwed shareholders. They need to axe their CBO and get someone that can make a deal. This last quarters dilution at stock price lows shows real desperation.
1 · Reply
Windytimes
Windytimes Aug. 16 at 1:40 PM
$CRBU https://www.genengnews.com/topics/bioprocessing/allogeneic-car-t-company-prepares-to-widen-access-to-patients/?utm_campaign=41123468-GEN_Editorial%20Social&utm_content=384251436&utm_medium=social&utm_source=linkedin&hss_channel=lcp-1385856
0 · Reply
HughGeez
HughGeez Aug. 14 at 6:36 PM
$CRBU We are in a much better position (based on the clinical results) than we were when the stock was $10, so hopefully we should return to at least there.
1 · Reply
Jidane
Jidane Aug. 14 at 4:02 PM
$CRBU No news, No update.
0 · Reply
biochirp
biochirp Aug. 14 at 1:57 PM
$CRBU theres the dump to sub 1.5
2 · Reply
Facade78
Facade78 Aug. 13 at 9:36 PM
$CRBU Good job ! Better results, 50% less operating expenses... Waiting for phase 3...
0 · Reply
HughGeez
HughGeez Aug. 13 at 9:27 PM
$CRBU It's also up after hours so I think most people agree.
0 · Reply
HughGeez
HughGeez Aug. 13 at 9:17 PM
$CRBU I am happy with the release. Looks like we are still on track.
0 · Reply
moneymikeC
moneymikeC Aug. 13 at 8:56 PM
$CRBU No real news. Good on cash burn rate decreasing
0 · Reply
Latest News on CRBU
Caribou Biosciences reports Q2 EPS (24c), consensus (31c)

2026-08-16T14:03:44.000Z - 2 days ago

Caribou Biosciences reports Q2 EPS (24c), consensus (31c)


Caribou Biosciences Quarterly report: Q2 2026

Aug 13, 2026, 4:00 PM EDT - 5 days ago

Caribou Biosciences Quarterly report: Q2 2026


Caribou Biosciences Earnings release: Q2 2026

Aug 13, 2026, 4:00 PM EDT - 5 days ago

Caribou Biosciences Earnings release: Q2 2026


Caribou Biosciences Transcript: AGM 2026

Jun 17, 2026, 10:30 AM EDT - 2 months ago

Caribou Biosciences Transcript: AGM 2026


Caribou Biosciences presents ANTLER trial results at EHA

2026-06-11T13:03:22.000Z - 2 months ago

Caribou Biosciences presents ANTLER trial results at EHA


Caribou Biosciences Slides: Corporate presentation

Jun 10, 2026, 7:00 AM EDT - 2 months ago

Caribou Biosciences Slides: Corporate presentation


Caribou Biosciences Proxy statement: Proxy filing

Jun 5, 2026, 8:00 AM EDT - 2 months ago

Caribou Biosciences Proxy statement: Proxy filing


Caribou Biosciences Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 3 months ago

Caribou Biosciences Quarterly report: Q1 2026


Caribou Biosciences Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 3 months ago

Caribou Biosciences Earnings release: Q1 2026


Caribou Biosciences Proxy statement: Proxy filing

May 1, 2026, 8:00 AM EDT - 3 months ago

Caribou Biosciences Proxy statement: Proxy filing


Caribou Biosciences Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 4 months ago

Caribou Biosciences Proxy statement: Proxy filing


Caribou Biosciences Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 4 months ago

Caribou Biosciences Proxy statement: Proxy filing


Caribou Biosciences Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 4 months ago

Caribou Biosciences Proxy statement: Proxy filing


Caribou Biosciences reports Q4 EPS (28c) vs. (39c) last year

2026-03-05T21:28:29.000Z - 5 months ago

Caribou Biosciences reports Q4 EPS (28c) vs. (39c) last year


Caribou Biosciences Annual report: Q4 2025

Mar 5, 2026, 3:00 PM EST - 5 months ago

Caribou Biosciences Annual report: Q4 2025


Caribou Biosciences Earnings release: Q4 2025

Mar 5, 2026, 3:00 PM EST - 5 months ago

Caribou Biosciences Earnings release: Q4 2025


Caribou Biosciences initiated with a Buy at Clear Street

2026-02-02T21:25:29.000Z - 7 months ago

Caribou Biosciences initiated with a Buy at Clear Street


Caribou Biosciences price target lowered to $6 from $8 at BofA

2026-01-06T15:15:25.000Z - 8 months ago

Caribou Biosciences price target lowered to $6 from $8 at BofA


Caribou Biosciences Slides: Corporate Presentation

Dec 3, 2025, 7:00 AM EST - 9 months ago

Caribou Biosciences Slides: Corporate Presentation


Caribou Biosciences reports Q3 EPS (30c) vs. (38c) last year

2025-11-12T22:25:13.000Z - 9 months ago

Caribou Biosciences reports Q3 EPS (30c) vs. (38c) last year


Caribou Biosciences Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 10 months ago

Caribou Biosciences Earnings release: Q3 2025


Caribou Biosciences Quarterly report: Q3 2025

Nov 12, 2025, 7:00 AM EST - 10 months ago

Caribou Biosciences Quarterly report: Q3 2025


Caribou Biosciences price target raised to $8 from $5 at Citi

2025-11-03T15:15:34.000Z - 10 months ago

Caribou Biosciences price target raised to $8 from $5 at Citi


Caribou Biosciences Transcript: Study Result

Nov 3, 2025, 8:00 AM EST - 10 months ago

Caribou Biosciences Transcript: Study Result


Caribou Biosciences Press release: Study Result

Nov 3, 2025, 8:00 AM EST - 10 months ago

Caribou Biosciences Press release: Study Result


Caribou Biosciences Slides: Study Result

Nov 3, 2025, 8:00 AM EST - 10 months ago

Caribou Biosciences Slides: Study Result


Caribou Biosciences Slides: Corporate Presentation

Aug 30, 2025, 7:00 AM EDT - 1 year ago

Caribou Biosciences Slides: Corporate Presentation


Caribou Biosciences Earnings release: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 1 year ago

Caribou Biosciences Earnings release: Q2 2025


Caribou Biosciences Quarterly report: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 1 year ago

Caribou Biosciences Quarterly report: Q2 2025


Caribou Biosciences Earnings release: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Caribou Biosciences Earnings release: Q1 2025


Caribou Biosciences Quarterly report: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Caribou Biosciences Quarterly report: Q1 2025


Caribou Biosciences Proxy statement: Proxy Filing

May 8, 2025, 8:00 AM EDT - 1 year ago

Caribou Biosciences Proxy statement: Proxy Filing


Caribou Biosciences Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Caribou Biosciences Proxy statement: Proxy Filing


Caribou Biosciences Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Caribou Biosciences Proxy statement: Proxy Filing


Caribou Biosciences Proxy statement: Proxy Filing

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Caribou Biosciences Proxy statement: Proxy Filing


HughGeez
HughGeez Aug. 18 at 11:34 AM
$CRBU I am no expert on Altimmune but didn't Altimmune drop because of mixed phase 2 results? We don't have that with CRBU. Also even though they had mixed phase 2 results the stock price is $3 with much higher market cap.
0 · Reply
cta7978
cta7978 Aug. 18 at 8:13 AM
$CRBU 3 quarters "exploring financing options", then last quarter dilluting nearly 10% at low stock price (~$2.03).. I fear they are going to have to go it alone.. Don't really understand why? I held Altimmune a few years ago, everyone was hoping for a partnership or a big pharma deal after phase 2, then everything just died and they did massive dilution and screwed shareholders. They need to axe their CBO and get someone that can make a deal. This last quarters dilution at stock price lows shows real desperation.
1 · Reply
Windytimes
Windytimes Aug. 16 at 1:40 PM
$CRBU https://www.genengnews.com/topics/bioprocessing/allogeneic-car-t-company-prepares-to-widen-access-to-patients/?utm_campaign=41123468-GEN_Editorial%20Social&utm_content=384251436&utm_medium=social&utm_source=linkedin&hss_channel=lcp-1385856
0 · Reply
HughGeez
HughGeez Aug. 14 at 6:36 PM
$CRBU We are in a much better position (based on the clinical results) than we were when the stock was $10, so hopefully we should return to at least there.
1 · Reply
Jidane
Jidane Aug. 14 at 4:02 PM
$CRBU No news, No update.
0 · Reply
biochirp
biochirp Aug. 14 at 1:57 PM
$CRBU theres the dump to sub 1.5
2 · Reply
Facade78
Facade78 Aug. 13 at 9:36 PM
$CRBU Good job ! Better results, 50% less operating expenses... Waiting for phase 3...
0 · Reply
HughGeez
HughGeez Aug. 13 at 9:27 PM
$CRBU It's also up after hours so I think most people agree.
0 · Reply
HughGeez
HughGeez Aug. 13 at 9:17 PM
$CRBU I am happy with the release. Looks like we are still on track.
0 · Reply
moneymikeC
moneymikeC Aug. 13 at 8:56 PM
$CRBU No real news. Good on cash burn rate decreasing
0 · Reply
biochirp
biochirp Aug. 13 at 8:46 PM
$CRBU Pfizer offically gone: Pfizer Investment For the three and six months ended June 30, 2025, we recognized $0.6 million and $1.2 million of revenue, respectively, from our Information Rights Agreement with Pfizer, dated June 29, 2023, which agreement expired on June 29, 2026, pursuant to which we had originally allocated $7.5 million as a contract with a customer under ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Pfizer ceased to be a related party as of December 31, 2025.
2 · Reply
Windytimes
Windytimes Aug. 13 at 8:29 PM
$CRBU dilution still a major possibility if they can’t find a partner, hopefully they see the value in CB-011 but CB-010 seems like a good alternative.
1 · Reply
Windytimes
Windytimes Aug. 13 at 8:27 PM
$CRBU burn rate was better…. But everything else was on par with what we already know. cb-011 is interesting but a small cohort, so hopefully more patients with similar to better results
0 · Reply
cta7978
cta7978 Aug. 13 at 8:09 PM
$CRBU https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-reports-second-quarter-2026-financial
0 · Reply
biochirp
biochirp Aug. 13 at 7:30 PM
0 · Reply
Nitro111
Nitro111 Aug. 13 at 3:34 PM
$CRBU Hope this stain on my portfolio does something after hours, crawling on last breaths at this point
1 · Reply
Windytimes
Windytimes Aug. 13 at 2:56 PM
$CRBU this doesn’t look promising unfortunately.
2 · Reply
Brandonswest
Brandonswest Aug. 13 at 5:05 AM
$CRBU looks like this one will quietly gain .02 a day forever. So that’s cool.
1 · Reply
Windytimes
Windytimes Aug. 12 at 8:07 PM
$CRBU I guess it’s tomorrow Lol
0 · Reply
HughGeez
HughGeez Aug. 12 at 8:03 PM
$CRBU I am really enjoying this ride up. Even though it's at a turtle's pace.
0 · Reply
biochirp
biochirp Aug. 12 at 7:04 PM
$CRBU if it breaks 1.5 is going to be a long road down
1 · Reply
KillOrder
KillOrder Aug. 12 at 4:56 PM
$CRBU when’s the next earnings call?
0 · Reply